The Weight-Loss Revolution People Didn’t Want

Most of the criticisms and rebuttals in this post are applicable to before 2024. By 2025, GLP-1 weight-loss drugs had become thoroughly mainstream and many skeptics have come around to the fact that these drugs are highly effective and that the side effects are manageable. But with the upcoming FDA approval of the potent triple-agonist Retatrutide, there has been renewed interest and skepticism, although less compared to pre-2024. A lot has changed since 2024. Eli Lilly’s tirzepatide portfolio (sold as Mounjaro for diabetes and Zepbound for weight loss) overtook Novo Nordisk’s Ozempic/Wegovy to become the top-selling drug globally. The tirzepatide and semaglutide shortages ended in late 2024, which was a big problem for diabetics. The class divide issue is mostly gone too, as the upper-middle class has embraced these drugs on social media, especially in tech after initial skepticism in 2022-2023. Often you’ll still see people conflating “lean mass loss” with “muscle loss”, but not…